quinta-feira, 8 de outubro de 2026
PesquisarExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· March 26, 2026

7 Signs Your 401(k) Is Quietly Underperforming

View original at finance.yahoo.com
7 Signs Your 401(k) Is Quietly Underperforming Quick Read iShares Core S&P 500 ETF (IVV) charges an expense ratio of 0.03%, the benchmark for low-cost index investing, while many 401(k) plans offer index-style funds charging over 0.5%—a gap that compounds into six-figure losses on a $500,000 balance over 20 years…
Opening lines of the source · short snapshot — read the full document at the original

O que extraímos desta fonte

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Many 401(k) plans offer index-style funds charging over 0.5%, a gap that compounds into six-figure losses on a $500,000 balance over 20 years compared to iShares Core S&P 500 ETF's 0.03% expense ratio

    60% confidence
  • Target-date funds from high-fee providers charge 0.6% to 0.8% annually compared to under 0.15% for low-cost alternatives

    60% confidence
  • Actively managed funds charge more and, over long periods, most underperform their benchmark indexes after fees

    60% confidence
  • Most 401(k) account holders unknowingly lose wealth through structural problems like excessive fees, concentrated employer stock positions above 10%, drift from target allocations, and failure to rebalance—costing participants tens of thousands in foregone compounding

    60% confidence
  • A $100,000 investment at a 7% gross annual return can grow substantially over 20 years at near-zero fees, while a 1% expense ratio meaningfully reduces that outcome

    60% confidence
  • Staying in a low-yielding default option while equity markets compound is one of the most expensive passive decisions a retirement saver can make

    60% confidence

Data points we hold from this source

Board of Governors of the Federal Reserve System · federal funds rate3.75 percent
O que sabemos · a inteligência por trás desta página
Ao vivo do substrato
O que estamos a ver
Autumn 2026 Biopharma Catalyst Season: Late-Breaking Data, FDA Milestones and the Rise of AI-Designed Drugs
Late-September and early-October 2026 conferences (EASD, EADV, IGCS) brought a cluster of positive late-breaking trial readouts. These covered obesity and metabolic disease (Novo Nordisk's CagriSema), immunology (Lilly's EBGLYSS, tulisokibart) and oncology (Rina-S, Agenus BOT+BAL). Ahead lie hard regulatory catalysts, led by the 14 Nov 2026 FDA PDUFA date for ivonescimab. At the same time, Insilico-style AI-designed drugs such as rentosertib are showing anti-aging signals. That points to AI-driven drug discovery moving from concept toward clinical validation. Unrelated tech and regulatory items (Tesla Cybercab probe, xAI litigation, OpenAI agent incident) and the speculative QAIAx claims are peripheral to this story.
A nossa leitura dos dados ›
Sinais que acompanhamos
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Padrões que observamos ›
Onde as fontes divergem
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Sinalizamos conflitos abertamente ›
Verificado recentemente
✓ Verificado com a fonte original
4,986
factos rastreados à sua fonte — e sinalizamos os que não se confirmam.
101 entidades acompanhadas4,986 factos verificados com a fonte5,362 documentos-fonte arquivados
Consulte estes dados → isubstrate.com